Protagonist Therapeutics' drug rusfertide reduced the need for phlebotomies as a way to treat the rare blood cancer polycythemia vera. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology.
Instead of viewing obesity as one uniform condition, experts now recognize that it can arise from multiple biological patterns. Understanding that difference could finally change how we approach treatment altogether.
At a recent behavioral health tech conference, Emily Durfee, a partner at Healthworx Ventures, shared her thoughts on how to differentiate mental health startups in an increasingly crowded market. She said it's important to figure out if the startup is solving a key problem for their customer — whether that's a provider, payer, employer or consumer.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
In this episode, we're joined by Liz Powell, founder of Women's Health Advocates. We discussed the organization's policy priorities in the women's health space.
No comments